Medshine Discovery Inc. has synthesized dimethyl-substituted thiazololactam compounds acting as mitogen-activated protein kinase 3 (MAPK3; ERK1) and/or (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer.